HCT-116 Orthotopic Mouse Model Service for Colon Cancer

The HCT-116 orthotopic mouse model anchors one of the most genetically well-characterized human colorectal carcinoma platforms available for preclinical investigation, combining a hypermutated, microsatellite-unstable phenotype with robust cecal engraftment potential and documented metastatic competence. Alfa Cytology constructs and manages this model with authenticated HCT-116 cell assets, precision surgical implantation protocols, and integrated longitudinal monitoring, equipping researchers with a dependable system for evaluating targeted therapeutics, combination regimens, and anti-metastatic strategies in a physiologically faithful colon microenvironment.

Overview of HCT-116 Orthotopic Mouse Model for Colon Cancer

The HCT-116 cell line was established in the late 1970s by D.L. Dexter from a primary colorectal adenocarcinoma resected from an adult male patient. This line is distinguished by a co-occurring oncogenic signature that includes a heterozygous KRAS p.G13D activating mutation and a heterozygous PIK3CA p.H1047R hotspot mutation, alongside wild-type BRAF and mutant TP53 status. Genomically, HCT-116 is classified as microsatellite instable (MSI-H) with a near-diploid karyotype and carries one of the highest somatic mutation rates among commonly used colorectal cancer lines. Morphologically, the cells present as small, epithelial-like adherent cells with a doubling time of approximately 18–20 hours under standard culture conditions. When implanted orthotopically into the murine cecal wall, HCT-116 tumors recapitulate the glandular architecture and invasive behavior of human colorectal adenocarcinoma, maintaining both KRAS-driven MAPK signaling and PI3K/AKT/mTOR pathway activation.

Fig 1. Longitudinal bioluminescence imaging of an orthotopic HCT116-Luc colorectal cancer xenograft model, allowing non-invasive monitoring of primary tumor growth, treatment response, and metastatic progression. (Kong, Chao, et al., 2023)

Orthotopic engraftment within the cecal mucosa and submucosa preserves the luminal epithelial interface, regional lymphatic drainage, and peritoneal dissemination routes that define clinical disease progression. This anatomical configuration supports spontaneous metastasis to the liver, lung, and peritoneal cavity, making the model invaluable for interrogating metastatic cascade mechanisms. The concurrent KRAS and PIK3CA mutations render HCT-116 particularly resistant to single-agent MEK inhibition while remaining responsive to dual PI3K/MEK blockade, 5-fluorouracil, and oxaliplatin-based regimens. Consequently, this orthotopic platform occupies a central position in preclinical pipelines targeting RAS-mutant colorectal cancer, combination pathway inhibition, and anti-metastatic drug discovery.

Cell Line Information: HCT-116

The following table presents a comprehensive compilation of the genetic, biological, and technical attributes of the HCT-116 human colorectal adenocarcinoma cell line, serving as a detailed reference for investigators designing preclinical studies in both in vitro and in vivo contexts.

Our Services

Alfa Cytology delivers a comprehensive HCT-116 orthotopic mouse model service purpose-built for advancing preclinical colorectal cancer research. Our offering encompasses authenticated HCT-116 master cell bank revival, mycoplasma screening, and expansion under rigorously monitored passage limits, followed by precision cecal wall surgical implantation in immunocompromised hosts. Longitudinal tumor monitoring is conducted via digital caliper measurement or optional bioluminescence imaging, while endpoint analyses span tumor biometrics, histopathology, immunohistochemistry, and molecular profiling. Every protocol parameter—from implantation cell density to dosing schedules and tissue harvest windows—is calibrated to your compound profile and translational objectives, ensuring data packages that satisfy peer-review and regulatory documentation standards.

Workflow of HCT-116 Orthotopic Mouse Model Construction

Construction of the HCT-116 orthotopic colon cancer model requires exacting surgical technique, stringent cell line quality control, and standardized perioperative care to achieve reproducible engraftment and meaningful therapeutic readouts. The protocol described below reflects a validated operational framework executed within specific pathogen-free barrier facilities, progressing through the following sequential stages:

1. Cell Line Authentication and Expansion: HCT-116 cells are revived from authenticated cryopreserved master stocks and expanded in McCoy's 5A medium supplemented with 10% heat-inactivated FBS. Prior to surgical use, cells undergo mandatory STR identity confirmation, mycoplasma PCR screening, and viability assessment by trypan blue exclusion to ensure a live-cell fraction exceeding 95%. For studies incorporating longitudinal imaging, HCT-116-Luc2 derivatives are validated for luciferase signal linearity in vitro prior to in vivo deployment.
2. Host Selection and Environmental Acclimation: Female or male athymic nude (nu/nu) or NOD/SCID gamma (NSG) mice aged 6–8 weeks are selected based on study design requirements. Animals are housed in specific pathogen-free vivaria under controlled temperature (22 ± 2°C), humidity (50 ± 10%), and a 12-hour light/dark cycle, with ad libitum access to irradiated chow and acidified water. A minimum five-day acclimation period is observed, during which baseline body weights and clinical scores are recorded.
3. Anesthesia and Aseptic Surgical Preparation: On the day of implantation, mice are anesthetized with 2–3% isoflurane inhalation delivered via nose cone, with anesthetic depth confirmed by absence of pedal withdrawal reflex. The ventral abdominal wall is shaved and sterilized with sequential povidone-iodine and 70% ethanol applications. Sterile surgical drapes are positioned to establish an aseptic operative field, and ophthalmic ointment is applied to prevent corneal desiccation.
4. Cecal Exposure and Orthotopic Cell Delivery: A 1.0–1.5 cm midline laparotomy is performed to access the peritoneal cavity. The cecum is gently exteriorized using atraumatic forceps and kept hydrated with warm sterile PBS. A single-cell suspension of 1 × 10⁶ viable HCT-116 cells, resuspended in 25–50 µL of serum-free McCoy's 5A medium mixed 1:1 with growth factor-reduced Matrigel, is loaded into a 1 mL syringe fitted with a 30 G needle. The needle is inserted into the subserosal plane of the cecal wall at the anti-mesenteric border, and the cell suspension is slowly deposited to form a discrete submucosal bleb without mucosal perforation.
5. Hemostasis, Cecal Repositioning, and Wound Closure: The injection site is compressed gently with a sterile cotton swab for approximately 3 minutes to ensure hemostasis and prevent cell leakage into the peritoneal cavity. The cecal wall is inspected for integrity, then gently returned to anatomical position within the abdomen. The abdominal musculature is closed with absorbable 5-0 sutures in a continuous pattern, and the skin is apposed with surgical staples or tissue adhesive. Mice are transferred to a warmed recovery chamber and monitored until full ambulatory recovery.
6. Postoperative Monitoring and Tumor Surveillance: During the immediate postoperative period, mice receive analgesia per institutional guidelines and are monitored daily for wound integrity, body weight, and clinical score. Tumor establishment is tracked twice weekly beginning approximately 7–10 days post-implantation. For HCT-116-Luc2 cohorts, tumor burden is quantified via IVIS bioluminescence imaging following intraperitoneal D-luciferin administration. Conventional groups are monitored by abdominal palpation and digital caliper measurement of externally palpable masses.
7. Stratified Randomization and Therapeutic Administration: Once tumors reach a predetermined volume or bioluminescence signal intensity—typically 100–200 mm³ or 10⁶ to 10⁷ photons/sec—mice are stratified by tumor burden and body weight into treatment and vehicle control cohorts. Investigational agents are administered according to predefined dosing regimens, with routes selected based on pharmacokinetic properties and mechanism of action. Concurrent tumor monitoring continues to capture real-time therapeutic response kinetics.
8. Necropsy, Triage, and Multi-Platform Endpoint Analysis: At study termination, mice are humanely euthanized under deep anesthesia. The cecum and primary tumor are excised en bloc, photographed, and weighed. Tumor tissue is triaged for formalin fixation and paraffin embedding (H&E, IHC for Ki-67, CD31, cleaved caspase-3, phospho-ERK, phospho-AKT), snap-freezing for Western blot or RNA-seq, and dissociation for flow cytometric analysis. Metastatic foci in mesenteric lymph nodes, liver, lung, and peritoneum are enumerated macroscopically and confirmed histologically.

Fig 2. HCT-116 Orthotopic Mouse Model construction workflow.

Case Study-HCT-116 Orthotopic Mouse Model Development

In a representative preclinical program, the HCT-116 orthotopic model was deployed to evaluate the efficacy of a dual-pathway inhibition strategy combining a PI3Kα-selective small-molecule inhibitor with a MEK1/2 antagonist in KRAS-mutant colorectal cancer. Following cecal wall implantation, tumor-bearing mice were stratified by tumor volume and randomized into monotherapy, combination, and vehicle control arms. Longitudinal monitoring revealed progressive tumor growth inhibition in the combination cohort beginning at day 10 post-treatment initiation, whereas single-agent arms showed only transient stabilization. Terminal histopathological analysis demonstrated markedly reduced Ki-67 proliferation indices and increased apoptotic fractions in combination-treated tumors, alongside attenuated phospho-AKT and phospho-ERK immunoreactivity. Metastatic nodules in the liver were significantly diminished in the dual-inhibition group compared to vehicle controls. These findings illustrate the translational utility of the HCT-116 orthotopic platform for discriminating combination synergy from single-agent activity and for generating mechanistic insights into co-targeting the KRAS/PI3K axis in colorectal adenocarcinoma.

Why Choose Alfa Cytology?

Collaborating with Alfa Cytology on your HCT-116 orthotopic model program provides access to a technically refined preclinical infrastructure optimized for colorectal cancer drug development. Our distinctive capabilities include:

• Authenticated HCT-116 master cell banks with documented STR profiles, mycoplasma negativity, and controlled passage limits to preserve the KRAS/PIK3CA double-mutant phenotype and MSI-H characteristics.
• Surgical teams experienced in cecal wall orthotopic implantation, achieving consistent tumor take rates with minimal perioperative complications and rapid postoperative recovery.
• Optional on-site IVIS bioluminescence imaging capability for non-invasive longitudinal tumor tracking in vivo, enabling real-time quantification of therapeutic response and metastatic progression.
• Flexible study designs accommodating monotherapy, combination, and sequential dosing paradigms, with stratified randomization based on tumor volume or bioluminescence signal intensity.
• Comprehensive endpoint triage delivering parallel histopathological, immunohistochemical (Ki-67, CD31, phospho-ERK, phospho-AKT), molecular, and flow cytometric datasets from a single tumor specimen.
• Dedicated project scientists who provide transparent milestone reporting, adaptive protocol adjustments, and publication-ready data compilation aligned to your translational milestones.

Contact Us

If your preclinical program requires a rigorously validated HCT-116 orthotopic model for evaluating KRAS/PI3K pathway inhibitors, combination regimens, or anti-metastatic agents, the scientific team at Alfa Cytology is prepared to design a customized study framework aligned with your therapeutic targets and regulatory objectives. Reach out to us today to discuss your project parameters, request a detailed service quotation, or schedule a technical consultation with our colorectal cancer model specialists.

For research use only. Not intended for any clinical use.